NuLYTELY

Manufacturer
Physicians Total Care, Inc.
Effective date
2009-10-15
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:11:58

Label at a glance#

ProductNuLYTELY
Active ingredientPOLYETHYLENE GLYCOL 3350, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE
Label structure11 sections

Indications and uses

NuLYTELY is indicated for bowel cleansing prior to colonoscopy.

Dosage and administration

NuLYTELY is usually administered orally, but may be given via nasogastric tube to patients who are unwilling or unable to drink the solution. Ideally, the patient should fast for approximately three or four hours prior to NuLYTELY administration, but in no case should solid food be given for at least two hours before the solution is given. Oral administration: Adults: At a rate of 240 mL(8 oz.) every 10 minutes, u...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION:

DESCRIPTION SECTION

A white powder for reconstitution containing 420 g polyethylene glycol 3350, 5.72 g sodium bicarbonate, 11.2 g sodium chloride, 1.48 g potassium chloride and one 2.0 g flavor pack (optional). When dissolved in water to a volume of 4 liters, NuLYTELY (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution) is an isosmotic solution having a pleasant mineral water taste. NuLYTELY is administered orally or via nasogastric tube as a gastrointestinal lavage. NuLYTELY Flavor Packs are available in Cherry, Lemon -Lime, Orange and Pineapple. This preparation can be used without the addition of a NuLYTELY Flavor Pack.

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

NuLYTELY induces a diarrhea which rapidly cleanses the bowel, usually within four hours. The osmotic activity of polyethylene glycol 3350 and the electrolyte concentration result in virtually no net absorption or excretion of ions or water. Accordingly, large volumes may be administered without significant changes in fluid or electrolyte balance.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

NuLYTELY is indicated for bowel cleansing prior to colonoscopy.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

NuLYTELY is contraindicated in patients known to be hypersensitive to any of the components. NuLYTELY is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon.

WARNINGS:

WARNINGS SECTION

NuLYTELY Flavor Packs are for use only in combination with the contents of the accompanying 4 liter container. No additional ingredients, e.g. flavorings, should be added to the solution. NuLYTELY should be used with caution in patients with severe ulcerative colitis. Use of NuLYTELY in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. Dehydration has been reported in 1 child and hypokalemia has been reported in 3 children.

PRECAUTIONS:

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: Patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration should be observed during the administration of NuLYTELY, especially if it is administered via nasogastric tube. If a patient experiences severe bloating, distention or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed to rule out these conditions before administration of NuLYTELY.

INFORMATION FOR PATIENTS SECTION

Information for patients: NuLYTELY produces a watery stool which cleanses the bowel before examination. Prepare the solution according to the instructions on the bottle. It is more palatable if chilled. For best results, no solid food should be consumed during the 3 to 4 hour period before drinking the solution, but in no case should solid foods be eaten within 2 hours of taking NuLYTELY.

Adults drink 240 mL (8 oz.) every 10 minutes. Continue drinking until the watery stool is clear and free of solid matter. This usually requires at least 3 liters. Any unused portion should be discarded. Pediatric patients (aged 6 months or greater) drink 25 mL/kg/hour. Continue drinking until the watery stool is clear and free of solid matter. Any unused portion should be discarded. Rapid drinking of each portion is better than drinking small amounts continuously. The first bowel movement should occur approximately one hour after the start of NuLYTELY administration. You may experience some abdominal bloating and distention before the bowels start to move. If severe discomfort or distention occur, stop drinking temporarily or drink each portion at longer intervals until these symptoms disappear.

Use of NuLYTELY in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. Dehydration has been reported in 1 child and hypokalemia has been reported in 3 children.

DRUG INTERACTIONS SECTION

Drug Interactions: Oral medication administered within one hour of the start of administration of NuLYTELY may be flushed from the gastrointestinal tract and not absorbed.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenic and reproductive studies with animals have not been performed.

PREGNANCY SECTION

Pregnancy: Category C. Animal reproduction studies have not been conducted with NuLYTELY. It is also not known whether NuLYTELY can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. NuLYTELY should be given to a pregnant woman only if clearly needed.

PEDIATRIC USE SECTION

Pediatric Use: Safety and effectiveness of NuLYTELY in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of NuLYTELY in adults with additional safety and efficacy data from published studies of similar formulations.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

Nausea, abdominal fullness and bloating are the most common adverse reactions (occurring in up to 50% of patients) to administration of NuLYTELY. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis and (rarely) anaphylactic reaction have been reported which may represent allergic reactions.

Published literature contains isolated reports of serious adverse reaction following the administration of PEG-ELS products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and “butterfly-like” infiltrate on chest X-ray after vomiting and aspirating PEG.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

NuLYTELY is usually administered orally, but may be given via nasogastric tube to patients who are unwilling or unable to drink the solution. Ideally, the patient should fast for approximately three or four hours prior to NuLYTELY administration, but in no case should solid food be given for at least two hours before the solution is given.

SPL UNCLASSIFIED SECTION

Oral administration: Adults: At a rate of 240 mL(8 oz.) every 10 minutes, until the rectal effluent is clear or 4 liters are consumed. Pediatric Patients (aged 6 months or greater): At a rate of 25 mL/kg/hour, until the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. Nasogastric tube administration: Adults: At a rate of 20-30 mL per minute (1.2-1.8 liters per hour). Pediatric Patients (aged 6 months or greater): At a rate of 25 mL/kg/hour, until the rectal effluent is clear.

The first bowel movement should occur approximately one hour after the start of NuLYTELY administration. Ingestion of 4 liters of NuLYTELY solution prior to gastrointestinal examination produces satisfactory preparation in over 95% of patients.

Various regimens have been used. One method is to schedule patients for examination in midmorning or later, allowing the patients three hours for drinking and an additional one hour period for complete bowel evacuation. Another method is to administer NuLYTELY on the evening before the examination.

SPL UNCLASSIFIED SECTION

Preparation of the solution: NuLYTELY solution is prepared by filling the container to the 4 liter mark with water and shaking vigorously several times to insure that the ingredients are dissolved. Dissolution is facilitated by using lukewarm water. The solution is more palatable if chilled before administration. However, chilled solution is not recommended for infants. The reconstituted solution should be refrigerated and used within 48 hours. Discard any unused portion.

HOW SUPPLIED:

HOW SUPPLIED SECTION

NuLYTELY, Cherry Flavor NuLYTELY, Lemon-Lime Flavor NuLYTELY, Orange Flavor NuLYTELY are available in a disposable jug, in powdered form, for oral administration as a solution following reconstitution.

4 liter Plastic Bottle     NDC 54868-4233-0

NuLYTELY with Flavor Packs is supplied in a disposable jug, in powdered form, for oral administration as a solution following reconstitution. Each jug has an attached package containing 4 flavor packs; one each 2.0 g: Cherry, Lemon-Lime, Orange and Pineapple flavoring, in powdered form, for the addition of ONE pack by the pharmacist prior to dispensing.

Each jug contains:

SPL UNCLASSIFIED SECTION

SPL UNCLASSIFIED SECTION

NuLYTELY: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g. When made up to 4 liters volume with water, the solution contains PEG-3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

SPL UNCLASSIFIED SECTION

Cherry Flavor NuLYTELY: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g and flavoring ingredients 2.0 g. When made up to 4 liters volume with water, the solution contains PEG-3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

SPL UNCLASSIFIED SECTION

Lemon-Lime Flavor NuLYTELY: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g and flavoring ingredients 2.0 g. When made up to 4 liters volume with water, the solution contains PEG-3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

SPL UNCLASSIFIED SECTION

Orange Flavor NuLYTELY: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g and flavoring ingredients 2.0 g. When made up to 4 liters volume with water, the solution contains PEG-3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

SPL UNCLASSIFIED SECTION

NuLYTELY with Flavor Packs: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g and flavoring ingredients 2.0 g (optional). When made up to 4 liters volume with water, the solution contains PEG-3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

SPL UNCLASSIFIED SECTION

STORAGE: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.

Distributed by Braintree Laboratories, Inc., Braintree, MA 02185

S 12/08


Relabeling of "Additional" label by:
Physicians Total Care, Inc.
Tulsa, OK     74146

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PAKAGE LABEL – PRINCIPAL DISPLAY PANEL

NDC 54868-4233-0

NuLYTELY®

(PEG-3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution)

With Flavor Packs

Rx Only

image of package label
image of package label

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
POLYETHYLENE GLYCOL 3350 Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813
POTASSIUM CATION Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813
SODIUM CATION Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9e37788c-b1bf-42ae-aac9-b60601606144Product name820260122
95250459-30e4-45c1-b08a-993044f49109Product name220250805
d9771140-739b-484b-ae64-b79528ff1211Product name320250801
efd58dcf-540a-4531-8766-e713129ca6f2Product name120250307
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
1527ac37-808d-43be-a63e-74e1258dbe46Product name920250219
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
bed0530e-f939-4541-956b-6928a2f6404fProduct name120241008
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name620240814
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
9fcb7a91-de07-4f00-aabf-e4d6fda403d5Product name820230322
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
0ec3537a-6c9b-432a-896c-b9ea8723049aProduct name920200701
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
7916de40-e296-41f0-b811-6d0df1a33e2cProduct name920180627
cefa60e2-a5b5-493e-9c54-24735b7dc509Product name220171212
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
d723478e-ad4a-ec23-6bd7-cfe33e1e3840Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-4233-0NuLYTELY4 L in 1 BOTTLE, PLASTICPOWDER, FOR SOLUTION41

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-4233NULYTELY (PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE AND POTASSIUM CHLORIDE) POWDER, FOR SOLUTION [PHYSICIANS TOTAL CARE, INC.]11 package rows20110517_b630fb8f-b6aa-4b94-a93c-d79f1626c05b.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
52268-400-01ML - Milliliter52268-400906ca043-fca4-4f7f-abc2-94d6fbe6995612012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
POLYETHYLENE GLYCOL 3350ACTIVE INGREDIENTG2M7P15E5P1
POTASSIUM CHLORIDEACTIVE INGREDIENT660YQ98I101
SODIUM BICARBONATEACTIVE INGREDIENT8MDF5V39QO1
SODIUM CHLORIDEACTIVE INGREDIENT451W47IQ8X1
POLYETHYLENE GLYCOL 3350ACTIVE MOIETYG2M7P15E5P1
POTASSIUM CATIONACTIVE MOIETY295O53K1521
SODIUM CATIONACTIVE MOIETYLYR4M0NH371
CHERRYINACTIVE INGREDIENTBUC5I9595W1
LEMONINACTIVE INGREDIENT24RS0A988O1
LIMEINACTIVE INGREDIENTC7X2M0VVNH1
ORANGEINACTIVE INGREDIENT5EVU04N5QU1
PINEAPPLEINACTIVE INGREDIENT2A88ZO081O1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-423354868-4233-0
52268-400

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 6 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
CHERRYCHERRYBUC5I9595WTABLET, CHEWABLE / ORALNAExact identifier — unii candidate
2 equally ranked IID candidates
PINEAPPLEPINEAPPLE2A88ZO081OPOWDER, FOR SUSPENSION / ORAL120 mgExact identifier — unii candidate
2 equally ranked IID candidates
LIMELIME (CALCIUM OXIDE)C7X2M0VVNHSOLUTION, CONCENTRATE / ORAL0.1 ml/1mlExact identifier — unii candidate
2 equally ranked IID candidates
LIMELIME (CALCIUM OXIDE)C7X2M0VVNHCAPSULE / ORALNAExact identifier — unii candidate
2 equally ranked IID candidates
CHERRYCHERRYBUC5I9595WTABLET / ORAL0.45 mgExact identifier — unii candidate
2 equally ranked IID candidates
PINEAPPLEPINEAPPLE2A88ZO081OCONCENTRATE / ORAL1 mg/1mlExact identifier — unii candidate
2 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N019797-001NULYTELYPOLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22
N019797-002NULYTELY-FLAVOREDPOLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
N019797-001AA
N019797-002AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22c2088c7a36db…
2026-10-15 13:18:302026-09N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18c2088c7a36db…
2026-09-14 22:38:342026-08N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-2284e616aacf4f…
2026-09-14 22:38:342026-08N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-1884e616aacf4f…
2026-08-18 06:07:402026-07N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22caaa826d4ba7…
2026-08-18 06:07:402026-07N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22011fe1cb6892…
2026-02-19 14:30 UTC2026-02N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-2231067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-226a471c1ec25d…
2025-08-23 18:47 UTC2025-08N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-2203ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-222680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-225bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22d06236e962d9…
2024-10-29 15:01 UTC2024-10N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-2279d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-22301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-221e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-228072bd15b7f6…
2024-05-31 18:47 UTC2024-05N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-225c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-225d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N019797-001NULYTELY420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1991-04-224b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N019797-002NULYTELY-FLAVORED420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOTFOR SOLUTION / ORALAARLD, RS1994-11-184b0b4de00fa7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09N019797-001AA1c2088c7a36db…
2026-10-15 13:18:302026-09N019797-002AA1c2088c7a36db…
2026-09-14 22:38:342026-08N019797-001AA184e616aacf4f…
2026-09-14 22:38:342026-08N019797-002AA184e616aacf4f…
2026-08-18 06:07:402026-07N019797-001AA1caaa826d4ba7…
2026-08-18 06:07:402026-07N019797-002AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N019797-001AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02N019797-002AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019797-001AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N019797-002AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08N019797-001AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08N019797-002AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019797-001AA1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N019797-002AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019797-001AA1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N019797-002AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019797-001AA103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N019797-002AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019797-001AA12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N019797-002AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019797-001AA15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N019797-002AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019797-001AA1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N019797-002AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N019797-001AA1d06236e962d9…
2024-10-29 15:01 UTC2024-10N019797-002AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019797-001AA179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N019797-002AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019797-001AA1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N019797-002AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019797-001AA11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N019797-002AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N019797-001AA18072bd15b7f6…
2024-05-31 18:47 UTC2024-05N019797-002AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019797-001AA15c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N019797-002AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N019797-001AA15d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N019797-002AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N019797-001AA14b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N019797-002AA14b0b4de00fa7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
fec3456a-b279-4603-ab4d-6a5a7df8c0a2b630fb8f-b6aa-4b94-a93c-d79f1626c05b2009-10-15Warnings, Adverse reactionsExact identifier
spl id: fec3456a-b279-4603-ab4d-6a5a7df8c0a2
spl set id: b630fb8f-b6aa-4b94-a93c-d79f1626c05b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.